

# Lingzhi Hong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/743157/publications.pdf>

Version: 2024-02-01

22  
papers

793  
citations

1040056

9  
h-index

940533

16  
g-index

22  
all docs

22  
docs citations

22  
times ranked

832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
2	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
3	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	1.1	109
4	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
5	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	7.0	80
6	Current and future treatment options for <i>MET</i> exon 14 skipping alterations in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199297.	3.2	40
7	Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors. <i>Scientific Reports</i> , 2014, 4, 5907.	3.3	37
8	Genetic Mutation Analysis of Human Gastric Adenocarcinomas Using Ion Torrent Sequencing Platform. <i>PLoS ONE</i> , 2014, 9, e100442.	2.5	15
9	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 33-40.	2.0	12
10	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021, 5, 1241-1249.	3.0	11
11	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9017-9017.	1.6	9
12	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping. <i>JCO Precision Oncology</i> , 2021, 5, 1802-1812.	3.0	9
13	Hint1 expression inhibits proliferation and promotes radiosensitivity of human SGC7901 gastric cancer cells. <i>Oncology Letters</i> , 2018, 16, 2135-2142.	1.8	8
14	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100237.	1.1	8
15	Protein phosphatase magnesium-dependent 1 is a novel tumor marker and target in hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2016, 10, 52-60.	3.4	5
16	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 3473.	3.7	5
17	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 172.	8.6	2
18	Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. <i>Cancers</i> , 2020, 12, 1903.	3.7	0

#	ARTICLE	IF	CITATIONS
19	Effect of H3K27 acetylation activated-long noncoding RNA CCAT1 on cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous carcinoma cell.. Journal of Clinical Oncology, 2016, 34, e15566-e15566.	1.6	0
20	Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC.. Journal of Clinical Oncology, 2022, 40, 9061-9061.	1.6	0
21	Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9055-9055.	1.6	0
22	Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21169-e21169.	1.6	0